Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Harvoni in chronic genotype 1 HCV infection
NCT02021656Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Dec 2013
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of ledipasvir in chronic hepatitis C virus infection (CHC), sponsored by Gilead Sciences. Primary endpoints: Sustained Virologic Response 12 Weeks After Discontinuation of Therapy and Percentage of Participants Who Permanently Discontinued Study Drug Due to an Adverse Event at 12 weeks. Started Dec 2013; status: completed.
02
Drugs
ledipasvir
03
Conditions
chronic hepatitis C virus infection (CHC)
Beyond the preview
Go deeper on NCT02021656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02021656.